|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
|
ES2984771T3
(es)
|
2012-06-13 |
2024-10-31 |
Incyte Holdings Corp |
Compuestos tricíclicos sustituidos como inhibidores de FGFR
|
|
US9765057B2
(en)
|
2012-12-20 |
2017-09-19 |
Merck Sharp & Dohme Corp. |
3-ester-4 substituted orexin receptor antagonists
|
|
EP2934517A4
(en)
|
2012-12-20 |
2016-05-25 |
Merck Sharp & Dohme |
2-PYRIDYLOXY-3-NITRIL-4-SUBSTITUTED OREXINE RECEPTOR ANTAGONISTS
|
|
LT2953952T
(lt)
*
|
2013-02-07 |
2017-08-25 |
Merck Patent Gmbh |
Makrocikliniai piridazinono dariniai
|
|
RS56331B1
(sr)
*
|
2013-02-07 |
2017-12-29 |
Merck Patent Gmbh |
Derivati piridazinon-amida
|
|
EA035095B1
(ru)
|
2013-04-19 |
2020-04-27 |
Инсайт Холдингс Корпорейшн |
Бициклические гетероциклы в качестве ингибиторов fgfr
|
|
TWI667233B
(zh)
*
|
2013-12-19 |
2019-08-01 |
德商拜耳製藥公司 |
新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
|
|
JP2017505337A
(ja)
|
2014-01-10 |
2017-02-16 |
アウリジーン ディスカバリー テクノロジーズ リミテッド |
Ｉｒａｋ４阻害剤としてのインダゾール化合物
|
|
PL3805233T3
(pl)
|
2014-01-13 |
2024-06-10 |
Aurigene Oncology Limited |
ENANCJOMERY (R) I (S) (S)-N-(5-(3-hydroksypirolidyn-1-ylo)-2-morfolinooksazolo[4,5-b]pirydyn-6-ylo)-2-(2-metylopirydyn-4-ylo)oksazolo-4-karboksyamidu jako inhibitory IRAK4 do leczenia nowotworu złośliwego
|
|
EP3200788B1
(en)
|
2014-09-30 |
2019-09-18 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
|
EP3200789B1
(en)
*
|
2014-09-30 |
2019-11-06 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
|
US9943516B2
(en)
|
2014-09-30 |
2018-04-17 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
|
US9969749B2
(en)
|
2014-09-30 |
2018-05-15 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
|
JO3705B1
(ar)
*
|
2014-11-26 |
2021-01-31 |
Bayer Pharma AG |
إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
|
|
EP3233840B1
(en)
|
2014-12-16 |
2018-11-21 |
Eudendron S.r.l. |
Heterocyclic derivatives modulating activity of certain protein kinases
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
ES2861351T3
(es)
|
2015-04-22 |
2021-10-06 |
Rigel Pharmaceuticals Inc |
Compuestos de pirazol y método para fabricar y usar los compuestos
|
|
EP3288558B1
(en)
|
2015-04-30 |
2022-05-11 |
Bayer Pharma Aktiengesellschaft |
Combinations of inhibitors of irak4 with inhibitors of btk
|
|
EP3195865A1
(de)
|
2016-01-25 |
2017-07-26 |
Bayer Pharma Aktiengesellschaft |
Kombinationen von irak4 inhibitoren und btk inhibitoren
|
|
US10435396B2
(en)
|
2016-03-03 |
2019-10-08 |
Bayer Pharma Aktiegesellschaft |
2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
|
|
EP3219329A1
(en)
|
2016-03-17 |
2017-09-20 |
Bayer Pharma Aktiengesellschaft |
Combinations of copanlisib
|
|
SI3448848T1
(sl)
|
2016-04-29 |
2024-01-31 |
Bayer Pharma Aktiengesellschaft |
Polimorfna oblika N-(6-(2-hidroksipropan-2-il)-2-(2-(metilsulfonil)etil)-2H-indazol-5-il) -6-(trifluormetil)piridin-2-karboksamida
|
|
PE20240651A1
(es)
|
2016-04-29 |
2024-04-04 |
Bayer Pharma AG |
Sintesis de indazoles
|
|
EP3464266B1
(en)
|
2016-06-01 |
2021-10-20 |
Bayer Animal Health GmbH |
Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals
|
|
JOP20180011A1
(ar)
|
2017-02-16 |
2019-01-30 |
Gilead Sciences Inc |
مشتقات بيرولو [1، 2-b]بيريدازين
|
|
CN120267671A
(zh)
|
2017-03-31 |
2025-07-08 |
奥锐金肿瘤有限公司 |
用于治疗血液病的化合物和组合物
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
CA3076613A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
KR20200073216A
(ko)
|
2017-10-19 |
2020-06-23 |
바이엘 애니멀 헬스 게엠베하 |
동물에서의 질환의 치료 및 방지를 위한 융합된 헤테로방향족 피롤리돈의 용도
|
|
JP7241747B2
(ja)
|
2017-10-31 |
2023-03-17 |
キュリス，インコーポレイテッド |
血液学的障害を治療するための化合物および組成物
|
|
WO2019111218A1
(en)
|
2017-12-08 |
2019-06-13 |
Cadila Healthcare Limited |
Novel heterocyclic compounds as irak4 inhibitors
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US11485743B2
(en)
|
2018-01-12 |
2022-11-01 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
EP3737675A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
GB201801226D0
(en)
|
2018-01-25 |
2018-03-14 |
Redx Pharma Plc |
Modulators of Rho-associated protein kinase
|
|
US11174257B2
(en)
|
2018-05-04 |
2021-11-16 |
Incyte Corporation |
Salts of an FGFR inhibitor
|
|
RS66310B1
(sr)
|
2018-05-04 |
2025-01-31 |
Incyte Corp |
Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
TWI842978B
(zh)
|
2018-07-13 |
2024-05-21 |
美商基利科學股份有限公司 |
衍生物
|
|
JP7623943B2
(ja)
|
2018-11-30 |
2025-01-29 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
CA3129601A1
(en)
|
2019-02-11 |
2020-08-20 |
Merck Patent Gmbh |
Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
CA3145043A1
(en)
*
|
2019-06-27 |
2020-12-30 |
Biogen Ma Inc. |
2h-indazole derivatives and their use in the treatment of disease
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CN114364674B
(zh)
|
2019-08-30 |
2025-10-03 |
里格尔药品股份有限公司 |
吡唑化合物，其配制品以及使用所述化合物和/或配制品的方法
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
AU2020360000B2
(en)
|
2019-10-02 |
2023-04-20 |
Kainos Medicine, Inc. |
N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient
|
|
PH12022550892A1
(en)
|
2019-10-14 |
2023-05-03 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
EP4051387B1
(en)
|
2019-10-31 |
2025-02-19 |
F. Hoffmann-La Roche AG |
Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
|
|
US12486273B2
(en)
|
2019-11-19 |
2025-12-02 |
Hoffmann-La Roche Inc. |
Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease
|
|
EP4069693B1
(en)
|
2019-12-03 |
2024-03-20 |
F. Hoffmann-La Roche AG |
Hydropyrido[1,2-alpha]pyrazine compounds for the treatment of autoimmune diseases
|
|
AU2020395185A1
(en)
|
2019-12-04 |
2022-06-02 |
Incyte Corporation |
Derivatives of an FGFR inhibitor
|
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US11591332B2
(en)
|
2019-12-17 |
2023-02-28 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
KR20220145325A
(ko)
|
2019-12-17 |
2022-10-28 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
US11866405B2
(en)
|
2020-12-10 |
2024-01-09 |
Astrazeneca Ab |
Substituted indazoles as IRAK4 inhibitors
|
|
AR124547A1
(es)
|
2020-12-30 |
2023-04-05 |
Kymera Therapeutics Inc |
Degradadores de irak y sus usos
|
|
MX2023009527A
(es)
|
2021-02-15 |
2023-08-24 |
Kymera Therapeutics Inc |
Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
|
|
WO2022187303A1
(en)
|
2021-03-03 |
2022-09-09 |
Rigel Pharmaceuticals, Inc. |
A method for treating a disease or condition using a pyrazole compound or formulation thereof
|
|
CN117120054A
(zh)
|
2021-04-08 |
2023-11-24 |
柯里斯公司 |
治疗癌症的组合疗法
|
|
JP2024513575A
(ja)
|
2021-04-12 |
2024-03-26 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
|
|
AR125798A1
(es)
|
2021-05-07 |
2023-08-16 |
Kymera Therapeutics Inc |
Degradadores cdk2 y usos de los mismos
|
|
TW202313610A
(zh)
|
2021-06-09 |
2023-04-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之三環雜環
|
|
WO2022261160A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
CA3223447A1
(en)
|
2021-06-25 |
2022-12-29 |
Korea Research Institute Of Chemical Technology |
Novel bifunctional heterocyclic compound having btk degradation function via ubiquitin proteasome pathway, and use thereof
|
|
EP4422635A4
(en)
|
2021-10-29 |
2025-11-26 |
Kymera Therapeutics Inc |
IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS
|
|
CA3243560A1
(en)
|
2022-01-31 |
2023-08-03 |
Kymera Therapeutics, Inc. |
Iraqi Degradation Agents and Their Uses
|
|
IL315677A
(en)
|
2022-03-23 |
2024-11-01 |
Rigel Pharmaceuticals Inc |
Pyrimid-2-yl-pyrazole compounds as irak inhibitors
|
|
KR102607237B1
(ko)
*
|
2023-06-07 |
2023-11-30 |
주식회사 젠센 |
신규한 트리아졸이 치환된 인다졸 유도체 및 이의 용도
|
|
WO2025036285A1
(zh)
*
|
2023-08-11 |
2025-02-20 |
深圳众格生物科技有限公司 |
一种降解irak4的蛋白降解靶向嵌合体化合物及其应用
|